Refractory, primary Central Nervous System Neoplasm Active Not Recruiting Phase 2 Trials for Selumetinib (DB11689)

Back to Refractory, primary Central Nervous System Neoplasm

Also known as: Refractory Primary Central Nervous System Neoplasm

IndicationStatusPhase
DBCOND0142769 (Refractory, primary Central Nervous System Neoplasm)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03213691Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Treatment